Twitter

Archive for June 15th, 2011


Combining Chemotherapy with Bevacizumab Improves Outcomes for Ovarian Cancer Patients

Results from two phase III randomized clinical trials suggest that, at least for some patients with ovarian cancer, adding the antiangiogenesis agent bevacizumab to chemotherapy increases the time to disease progression and may improve survival. Longer follow-up is needed to confirm the trends, but, if upheld, the results of these trials would support the first use of a biologic agent to treat ovarian cancer. Data from both trials were presented last week at the ASCO annual meeting in Chicago.

Read More...

Let’s be bloody minded

… which the number of donors drops. Former England footballer Gary Linekers son George survived leukaemia as a baby, with the help of blood transfusions, and this year the TV …

Read More...

High-Dose Methotrexate Extends Event-Free Survival for Children with Leukemia

Children’s Oncology Group researchers have shown in a phase III clinical trial that radically increasing the dose of methotrexate used to treat patients with high-risk B-cell acute lymphoblastic leukemia (B-cell ALL) significantly improves 5-year event-free survival (that is, survival without any serious health events) when compared with the current standard of care. The trial results were presented last week at the ASCO annual meeting.

Read More...

100 brave daredevils wanted for record bid

… fun or raise money for a charity, including Afghan Heroes, Families for Children, Exeter Leukaemia Fund (ELF), St Loye’s Foundation, Brainwave and Country Holidays for Inner City Kids (CHICKS). …

Read More...

Longer Imatinib Treatment for GIST Improves Survival

Prolonging treatment of patients with high-risk gastrointestinal stromal tumors (GIST) with the tyrosine kinase inhibitor imatinib (Gleevec) after surgery improved overall and recurrence-free survival in a prospective randomized multicenter trial. The trial results were presented June 5 at the ASCO annual meeting by lead author Dr. Heikki Joensuu of Helsinki University Central Hospital, Finland.

Read More...

QIAGEN makes proposal to fully ac…

… designed for specific needs in terms of diagnosis, prognosis and monitoring: BCR-ABL (Chronic Myeloid Leukemia) JAK2 V617F (various myeloproliferative diseases) PML-RARA (Promyelocytic Leukemia) A group of several products for …

Read More...

New Therapies Offer Much-Needed Options for Patients with Melanoma

The much-anticipated findings from two phase III clinical trials of new therapies for patients with metastatic melanoma did not disappoint those in attendance at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago last week.

Read More...

QIAGEN Makes Proposal to Fully Acquire Ipsogen, Further Expanding Leadership in Oncology Molecular Diagnostics

… for specific needs in terms of diagnosis, prognosis and monitoring: – BCR-ABL (Chronic Myeloid Leukemia) – JAK2 V617F (various myeloproliferative diseases) – PML-RARA (Promyelocytic Leukemia) – A group of …

Read More...

Prevention Of Prostate Cancer Part 3

www.balancedhealthtoday.com www.balancedhealthtoday.com www.balancedhealthtoday.com Side Effects Of Prostate Cancer Androgen Hormone Therapy Antiandrogens are medications such as flutamide, bicalutamide, nilutamide, and cyproterone acetate which directly block the actions of testosterone and DHT within prostate cancer cells. They are a form of hormonal therapy which, in the treatment of prostate cancer, makes use of such medications (otherwise orchiectomy) to block prostate cancer cells from getting the dihydrotestosterone (DHT) hormone that is required for their growth and spread. This way these androgen treatments cause the tumor to stop growing and even shrink. Although they rarely cure the disease (since the cancers generally become resistant after a while), they are a good way to slow the disease down, especially when it is metastasizing. Prostate cancer hormone therapy is also called androgen deprivation therapy (ADT) or androgen suppression therapy because of this. The androgens, produced mainly in the testicles, stimulate prostate cancer cells to grow; and as stated in the previous chapter, lowering their levels in the patient often causes the cancer shrink or grow more slowly. www.balancedhealthtoday.com www.balancedhealthtoday.com

Read More...

FDA issues new sunscreen guidelines

The FDA is issuing the first new sun block guidelines in over thirty years. Betty Nguyen reports, the goal is to reduce skin cancer by changing the labels on sunscreen products.

Read More...